ArticleNeurological research and practice2025
Ketogenic diet for status epilepticus in adult intensive care unit patients: a standard operating procedure.
Article in Neurological research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Comment on: ketogenic diet for status epilepticus in adult intensive care unit patients: a standard operating procedure.Neurological research and practice · 2026Article
- Clinical outcomes and unmet therapeutic needs in new-onset refractory status epilepticus: evidence from a retrospective cohort.Neurological research and practice · 2026Article
- Ketogenic Diet for Intensive Care Patients: A Scoping Review.Nutrients · 2026Article
- Current concepts on feeding the critically ill patient: a narrative review.Critical care (London, England) · 2026Review
- Ketogenic Diet in Super-Refractory Status Epilepticus: A Retrospective Cohort Study with Severity-Matched Controls in Critically Ill Adults.Neurocritical care · 2026Article
- Preventive strategies in neuroimmunology.Neurological research and practice · 2026Review
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRefractory and super-refractory status epilepticus (RSE and SRSE) are life-threatening neurological emergencies with significant morbidity and mortality. When conventional treatment strategies, including antiseizure medications (ASM) and anesthetic agents, fail, alternative metabolic approaches, such as the ketogenic diet (KD), have been considered. KD is a high-fat, low-carbohydrate, and adequate-protein diet that induces ketosis, exerting anticonvulsant effects. Different types of KD are available, including the classical KD and the modified Atkins diet (MAD). Most published evidence in RSE and SRSE stems from classical KD protocols with high fat-to-carbohydrate/protein ratios (e.g., 4:1), whereas evidence for MAD in this setting is limited, and outcome equivalence across KD types remains unclear. While emerging evidence suggests efficacy in RSE and SRSE, clinical application in adult intensive care unit (ICU) settings remains inconsistent. This standard operating procedure (SOP), developed collaboratively by neurologists, intensivists, anesthesiologists, and clinical nutrition experts, provides a structured framework for classical KD implementation in adult ICU patients with RSE and SRSE, covering indications, contraindications, initiation, monitoring, and safety considerations. DEFINITION: KD is a metabolic therapy that induces ketosis, providing an alternative energy source for the brain while modulating neurotransmitter activity and neuronal excitability. FIRST STEPS: KD should be considered in RSE persisting for > 72 h despite adequate antiseizure treatment or in SRSE early after ICU admission, preferably within 24 h. Before initiation, metabolic screening is required, including tests on liver and renal function, lipid profile, electrolyte balance, and glucose metabolism. Absolute contraindications, such as severe hepatic dysfunction, ileus, or severe hypertriglyceridemia, must be ruled out. Continuous EEG monitoring should be considered. The diet is typically initiated using a classical KD protocol with a 4:1 lipid-to-non-lipid ratio formula and stepwise fat increase, supplemented with medium-chain triglyceride (MCT) oil to enhance ketosis. Essential micronutrients, including carnitine, vitamins, and trace elements, should be supplemented routinely based on clinical indication to prevent deficiencies. COMMENTS: KD initiation follows a stepwise protocol with enteral formulations. Strict biochemical monitoring is essential to ensure metabolic stability, focusing on glucose, ketone levels, lipid profiles, liver function, and acid-base balance. Adverse effects, including metabolic acidosis, hypoglycemia, and hyperlipidemia, require timely adjustments. Involvement of an experienced dietician for nutritional support, trained nursing staff, as well as close interdisciplinary coordination are critical for successful initiation and maintenance of KD and for minimizing complications, particularly in centers with limited KD experience due to lack of familiarity with ketosis-impeding factors such as carbohydrate-containing medications. The suggested flowchart provides a structured approach for decision-making, highlighting indications, monitoring strategies, and emergency discontinuation criteria.
conclusionThis SOP provides a standardized, interdisciplinary protocol for classical KD implementation in adult ICU patients with RSE and SRSE. Developed collaboratively it integrates current literature and institutional experience. Despite heterogeneous study results, we advocate for early KD initiation in all SRSE patients without contraindications, given its safety, reversibility, and rapid implementability. By enhancing reproducibility and clinical feasibility, this SOP offers a practical and transferable tool for neurocritical care. We encourage other centers to adapt and apply this approach to further validate its utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.